WO1997005248A2 - Solution containing chaotropic agent and process using it for isolation of dna, rna and proteins - Google Patents
Solution containing chaotropic agent and process using it for isolation of dna, rna and proteins Download PDFInfo
- Publication number
- WO1997005248A2 WO1997005248A2 PCT/US1996/011875 US9611875W WO9705248A2 WO 1997005248 A2 WO1997005248 A2 WO 1997005248A2 US 9611875 W US9611875 W US 9611875W WO 9705248 A2 WO9705248 A2 WO 9705248A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- dna
- homogenate
- rna
- organic solvent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
Definitions
- the invention relates to compositions and methods for isolating nucleic acids (both RNA and DNA) and proteins from biological materials. And more particularly, the invention relates to nucleic acid and protein isolation methods employing non-toxic chaotropic agents.
- PCR polymerase chain reaction
- mRNA messenger RNA
- RT-PCR reverse transcription PCR
- RNA, DNA and proteins three cellular components
- the simultaneous isolation is especially important when the sample size is so small, such as in biopsy, that it precludes its separation into smaller samples to perform separate isolation protocols for DNA, RNA and proteins.
- isolating DNA, RNA and proteins from a single biological material sample One such method is described in Coombs, L. M., et al.: "Simultaneous Isolation of DNA, RNA and Antigenic Protein Exhibiting Kinase Activity from Small Tumor Samples Using Guanidine Isothiocyanate", Anal. Biochem.. 188, 338-343 (1990).
- the Coombs et al. method is based on ultracentrifugation of the sample homogenate in a guanidine- cesium chloride solution.
- the sample is homogenized in 4 M guanidine thiocyanate and then overlayered on a cesium chloride (CsCl) solution and centrifuged at > 100,000g for about 18 hours. Following centrifugation, DNA, RNA and proteins are separated and purified over the next 12-24 hours.
- This method has several limitations or drawbacks, including the prolonged time required for isolation and the limited number and size of samples which can be processed with an ultracentrifuge. Also, the high cost of an ultracentrifuge may be prohibitive in certain circumstances.
- DNA isolation methods There are many known methods for the separate isolation of DNA, RNA and proteins from biological material; i.e., protocols for isolating a single one of these components from a sample.
- a biological sample is lysed in a lysing solution and then the DNA is isolated from the lysate according to any one of a variety of multi-step protocols, which may take from one hour to several days to complete.
- Frequently recommended DNA isolation methods involve the use of toxic phenol. See, Sambrook, J. et al., "Molecular Clomng", Vol. 2, pp. 9.14-9.23,
- RNA and DNA are derived from DNA.
- a biological sample is lysed in a detergent solution and the protein component of the lysate is digested with proteinase for 12 - 18 hours.
- the lysate is extracted with phenol to remove most of the cellular components, and the remaining aqueous phase is processed further to isolate DNA.
- non-corrosive phenol derivatives are used for the isolation of nucleic acids.
- the resulting preparation is a mix of RNA and DNA.
- DNA isolation methods utilizing non-corrosive chaotropic agents have also been developed. These methods, which are based on the use of guanidine salts, urea and sodium iodide, involve lysis of a biological sample in a chaotropic aqueous solution and subsequent precipitation of the crude DNA fraction with a lower alcohol. The final purification of the precipitated, crude DNA fraction can be achieved by any one of several methods, including column chromatography as described in "RapidPrepTM Genomic DNA Isolation Kits For Cells and Tissue: Versatility at Your Fingertips!, Analects. Vol 22, No. 4, Pharmacia Biotech, 1994, or exposure of the crude DNA to a polyanion- containing protein as described in Koller U.S. Patent 5,128,247.
- cytoplasmic proteins and RNA are removed by lysing cell samples in a detergent solution.
- the lysate is then fractionated into the nuclear and cytoplasmic fractions.
- the DNA is purified by dissolving the nuclear fraction in a chaotropic solution, precipitating and washing with ethanol.
- This method described in Ciulla, T.A. et al., "A Simple Method for DNA Purification from Peripheral Blood", Anal. Biochem. 174, 485-488 (1988), can be completed in about 2 hours and is useful for isolating DNA from whole blood.
- RNA isolating RNA typically utilize either guanidine salts or phenol extraction, as described for example in Sambrook, J. et al., "Molecular Cloning", Vol. 1, pp. 7.3-7.24, Cold Spring Harbor Laboratory Press (1989) and Ausubel, F. M. et al., "Current Protocols in
- the products and methods of the present invention provide a highly effective, simple means of extracting DNA, RNA and proteins from a single biological material sample, such as cells, tissues and biological fluids.
- a single biological material sample such as cells, tissues and biological fluids.
- these results can be achieved without the use of toxic or corrosive reagents and without the use of expensive ultracentrifugation equipment.
- Genomic DNA and total RNA can be isolated utilizing the products and methods of the invention in as little as 20 minutes, and proteins in as little as 30 minutes. These results are substantially faster than existing methods for the simultaneous isolation of DNA, RNA and proteins.
- the invention is also applicable to the separate isolation of RNA only, DNA only, proteins only or any combination of two of these cellular components.
- the resulting genomic DNA and total RNA isolated utilizing the methods and products ofthe invention are of high quality suitable for use in research, biotechnology, etc.
- the invention is in part based on the unexpected finding that utilizing the products of the invention, RNA is precipitated prior to DNA, which is contrary to prior art methodologies.
- the finding that the solvent solution of the present invention precipitates RNA prior to DNA is in striking contrast to the described prior art such as Koller U.S. Patent No. 5,128,247, wherein it describes that DNA exhibits a lower solubility than RNA and apparently can be precipitated more easily than RNA.
- substantially lower amounts of organic solvents are required to effect the precipitation of the cellular components.
- the invention encompasses solutions for isolating substantially pure and undegraded RNA, DNA and protein from biological materials, including tissue, cells and fluids.
- the solution preferably includes effective amounts of a chaotropic agent(s), buffer, reducing agent, and water (with or without organic solvent(s)).
- the chaotropic agent(s) act to dissociate proteins from nucleic acids (RNA and DNA) and inhibit the activity of nucleic acid degradation enzymes.
- the actions of the chaotropes are potentiated by the reducing agent present in the solvent solution.
- the solution includes an organic solvent, its presence prevents solubilization of
- RNA thereby making it possible to remove RNA from the homogenate formed when the tissue sample is homogenized in the solvent solution by a brief centrifugation step.
- the RNA is precipitated from the homogenate subsequent to homogenization by the addition of an organic solvent.
- Preferred chaotropic agents for the solution include guanidine thiocyanate, guanidine hydrochloride, and mixmres thereof. These components may be supplemented with other chaotropes, such as urea or sodium iodide.
- the preferred concentration of chaotropes in the solution is in the range of about 2 M - 7 M.
- the reducing agent is non-toxic, such as 2- aminoethane thiol. If required, this can be substituted with 2-mercaptoethanol; however, this is a toxic composition.
- the reducing agent facilitates denaturization of RNase by the chaotropes and aids in the isolation of undegraded RNA.
- the solution of the present invention preferably contains a sufficient amount of buffer to maintain the pH of the solution above about 6.
- the pH should be maintained in the range of about 6-7.5.
- the effective pH range may be about 6-12.
- the preferred buffers for use in the solutions of the invention include tris-hydrochloric acid, sodium phosphate, sodium acetate, sodium tetraborate-boric acid and glycine-sodium hydroxide.
- the solution may contain an organic solvent.
- the preferred solvents are lower alcohols such as methanol, ethanol and isopropanol.
- water miscible solvents can be used which will achieve the desired effect, such as acetone, polyethylene glycol and dimethylsulfoxide, or mixtures of any of the foregoing.
- the effective concentration of organic solvents in the product of the invention is in the range of about 15-30% by volume.
- the solution of the invention may contain additional components, including organic and inorganic salts such as sodium chloride, potassium chloride, ammonium chloride, sodium phosphate, sodium acetate, sodium nitrite, lithium chloride, and sodium bromide.
- organic and inorganic salts such as sodium chloride, potassium chloride, ammonium chloride, sodium phosphate, sodium acetate, sodium nitrite, lithium chloride, and sodium bromide.
- compatible detergents such as sarcosines and polyoxyethylenesorbitan
- chelating agents such as ethylenediamine tetraacetic acid and citric acid can be utilized to promote tissue solubilization and precipitation of nucleic acids.
- the invention encompasses methods of isolating substantially pure RNA, DNA and proteins from biological material samples. Utilizing the solutions of the present invention, and particularly those wherein the solution includes an organic solvent, the method includes an initial step of homogenizing a biological material sample in the solution to form an homogenate. The presence of the organic solvent prevents
- RNA thereby making it possible to remove RNA from the homogenate by brief centrifugation (sedimentation). Thereafter, DNA is precipitated from the remaining homogenate by adding an effective amount of an organic solvent and recovering the precipitated DNA by brief centrifugation (sedimentation). Finally, adding an effective amount of an organic solvent to the remaining homogenate precipitates proteins therefrom.
- the successive addition of organic solvents to precipitate genomic DNA and proteins from the post-RNA homogenate require a limited amount of the organic solvent. Following a wash with ethanol, the three cellular components are each separately and fully ready for use in molecular biology, biotechnology and clinical research applications.
- the organic solvent utilized to precipitate DNA is added in a ratio of about 0.15-0.3 volumes of solvent per one volume of initial homogenate.
- the organic solvent added to precipitate proteins is preferably added in the ratio of about 3-4 volumes of solvent per one volume of initial homogenate.
- One preferred organic solvent for this purpose is isopropanol, although other suitable organic solvents can be used.
- the homogenate is formed and an initial centrifugation step is performed to remove any unhomogenized tissue.
- an organic solvent is added to preclude the solubilization of total RNA.
- an organic solvent added to precipitate RNA is added in a ratio of about 0.15-0.3 volumes of solvent per one volume of initial homogenate.
- RNA is washed with ethanol and the RNA precipitate may be dissolved in formamide and stored at -20" C.
- formamide as a solubilization agent is beneficial in that it protects RNA from degradation by RNase, which may otherwise contaminate the isolated RNA.
- DNA is precipitated by adding an additional 0.15-0.3 volumes of organic solvent per one volume ofthe initial homogenate.
- the DNA precipitate is removed from the homogenate by spooling or brief centrifugation (sedimentation). Proteins and other cellular components are retained in the homogenate and the protein component is precipitated by the addition of 3-4 volumes of an organic solvent per one volume of the initial homogenate.
- the precipitation of nucleic acids according to the present invention is performed with a substantially reduced amount of organic solvents.
- organic solvents for example, in
- RNA precipitation requires the addition of 0.5-2.5 volumes of a lower alcohol added to one volume of the chaotropic solution.
- the RNA precipitation was carried out for several hours at -20-4 * C.
- the precipitation of RNA according to the present method is completed in about 3-5 minutes and is performed at room temperamre.
- Botwell, D.D.L. Rapid Isolation of Eukaryotic DNA", Anal. Biochem. 162, 463-465 (1987), describes precipitation from chaotropic solutions carried out with 2-2.5 volumes of ethanol.
- Fig. IA shows the electrophoretic analysis of nucleic acids isolated in accordance with Example 1 herein;
- Fig. IB shows the utility of the total RNA in RT-PCR
- Fig. IC shows the utility of the genomic DNA in PCR
- Fig. ID shows the results of protein analysis by Western blotting
- Fig. 2A shows the electrophoretic analysis of nucleic acids isolated in accordance with Example 2 herein;
- Fig. 2B shows the results of total RNA analysis by Northern blotting
- Fig. 2C shows the results of genomic DNA analysis by Southern blotting
- Fig.2D shows the results of protein analysis by Western blotting
- FIG. 3 shows the results of genomic DNA analysis by electrophoresis as isolated in Example 5.
- Example 1 Simultaneous Isolation of DNA. RNA & Proteins From Cells A method of the invention was used to simultaneously isolate
- DNA, RNA and proteins from rat somatomammotroph PO cells were lysed (homogenized) in a 10ml of solution of the invention, which contained: 4 M guanidine thiocyanate (Amresco, Inc., Solon, OH), 17% isopropanol, 0.1 M sodium acetate, 0.1 M 2-aminoethanethiol hydrochloride (Sigma, St. Louis, MO) and 0.2% sarkosyl in water. The solution was adjusted to pH 7.0 with hydrochloric acid. Unless stated otherwise, chemical reagents were obtained from Fisher Scientific (Pittsburgh, PA). Next, 0.6 ml aliquots of the lysate (homogenate) were frozen or used immediately for the isolation. The 0.6 ml aliquot utilized as described below contained 37.3 ⁇ g DNA, as determined by the diphenylamine reaction.
- RNA-solubilized formamide For use in the reverse transcription PCR (RT-PCR), an aliquot of the RNA-solubilized formamide was precipitated with 3 volumes of ethanol. The precipitate was dissolved in water and used for RT-PCR.
- RNA and DNA are substantially improved when performed in a solution containing higher than usual concentrations of chelating agents.
- concentration of chelating agent(s) should be higher than 5 mM, with the optimum for ethylenediamine tetraacetate (EDTA) at 10 mM and for citrate at 30 mM. This is a new and unexpected finding.
- EDTA ethylenediamine tetraacetate
- optical density readings of RNA and DNA are performed in water or 1 mM EDTA.
- the optical density readings are more reproducible and result in a higher 260/280 ra ⁇ o.
- the RNA preparation described in Example 1 had a 260/280 ratio of
- DNA isolation DNA was precipitated from the post-RNA lysate by the addition of 0.15 ml of isopropanol. The floating DNA precipitate was swirled (spooled) onto the pipette tip and transferred to a new tobe. The remaining post-DNA lysate was saved for the protein isolation described below.
- the DNA was washed by mixing it with 1 ml of 95% ethanol and pipetting out the ethanol wash. The final DNA preparation was dissolved in 8 mM NaOH by gentle pipetting followed by neutralization of the solution with N-[2- hydroxyethyl] piperazine-N-[2-ethane sulfinic acid] (HEPES, free acid). The isolation was completed in less than 14 minutes.
- the method of the invention provided 91 % recovery of DNA.
- Protein isolation Proteins were precipitated from the post-DNA lysate by the addition of 1.8 ml of isopropanol and centrifugation at 10,000 g for 5 minutes. The precipitate was washed with 95% ethanol and dissolved in 0.1 N acetic acid. Alternatively, the precipitate could be dissolved in 0.1% sodium dodecylsulphate, or in water. The protein isolation was completed in 22 minutes. The isolated protein preparation was tested by Western blotting using a specific anti-rat prolactin antibody. The presence ofthe prolactin specific band in Western blotting is indicative of the good quality of the isolated protein preparation.
- Figure 1 A shows the results of nucleic acids electrophoresed in 1 % agarose gel and stained with ethidium bromide. Lanes 1 and 2 show undegraded total RNA (3 ⁇ g/lane); lanes 3 and 4 show high molecular weight genomic DNA (3 ⁇ g/lane); and lanes 5 and 6 show genomic DNA (3 ⁇ g) digested for 2 hours with EcoRI restrictase. As the results demonstrate, there is no detectable DNA in the RNA preparation and no detectable RNA in the DNA preparation. The total digestion of DNA by EcoRI restrictase is indicative of the good quality of the isolated DNA.
- Figures 1B-D show the results of RT-PCR, PCR and Western blotting performed with total RNA, genomic DNA and proteins, respectively, isolated as described hereinabove.
- the RT-PCR (Fig. IB) and PCR (Fig. IC) were performed using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and rat growth hormone (GH) primers, respectively, and Western blotting (Fig. IC) was performed using anti-rat prolactin antibody.
- Amplification of the 374 base pair GAPDH DNA fragment in RT-PCR and the 686 base pair GH DNA fragment in PCR indicates that the isolated nucleic acid preparations (RNA and DNA) are adequately purified for the PCR reaction.
- the presence of a prolactin specific band in Western blotting shows the high quality of the isolated protein preparation.
- EXAMPLE 2 Simultaneous Isolation of RNA, DNA and Proteins From Tissues.
- the solution does not include an organic solvent component. This permits the removal of any ⁇ nhomogenized tissue fragments from the lysate (homogenate) by a brief initial centrifugation. Thereafter, RNA is precipitated from the clear lysate by the addition of 0.2-0.3 volumes of an organic solvent.
- a frozen sample of rat pituitary was homogenized in a hand held glass-Teflon homogenizer with 1 ml of a lysing solution containing 4 M guanidine thiocyanate, 0.1 M sodium acetate, 0.1 M 2-aminoethanethiol hydrochloride and 0.2% sarkosyl in water.
- the solution was adjusted to pH 7.0 with hydrochloric acid.
- the homogenate was centrifuged at 10,000 g for 5 minutes. The clear supernatant was transferred to a new tobe, mixed with 0.3 ml of isopropanol and stored for 3 minutes at room temperature to precipitate
- RNA The precipitated RNA was removed by centrifugation at 10,000 g for 8 minutes and dissolved in formamide. The post-RNA supernatant was further processed to isolate DNA and proteins in the same manner as described in Example 1. DNA and proteins were successively precipitated from the post- RNA lysate by the addition of 0.5 ml acetone and 10.75 ml of acetone, respectively. The isolated RNA exhibited a 260/280 ratio of 1.74 and the yield was 0.06 mg. The DNA exhibited a 260/280 ratio of 1.78 and the yield was 0.04 mg. As shown in Figure 2 A, there was no detectable DNA present in the RNA preparation and no detectable RNA present in the DNA preparation. As in Fig.
- Figs. 2B-D show that the method of invention yielded high quality RNA, DNA and protein preparations.
- Example 1 The lysing solution used was that in Example 1. The lysate was centrifuged at 10,000 g for 5 minutes, and the RNA pellet was washed with
- RNA exhibited a
- Rat kidney (0.95 g) was homogenized in 19 ml of a lysing solution having the following composition: 4 M guanidine thiocyanate, 0.1 M sodium acetate and 0.2% sarkosyl in water. The solution was adjusted to pH 7.0 with hydrochloric acid. The homogenate was centrifuged at 10,000 g for
- the lysing solution used for this DNA isolation contained the following: 4 M guanidine thiocyanate, 0.1 M sodium acetate, 17% isopropanol,
- Rat pituitary P0 cells were lysed in the lysing solution by repetitive pipetting.
- the lysate was mixed with 0.4 volume of ethanol and the precipitated DNA was spooled onto a pipette tip and washed twice with 95% ethanol.
- the resulting DNA was dissolved in 8 mM NaOH and neutralized to pH 8.0 with 0.1 M HEPES buffer.
- This embodiment of the invention further shortens the DNA isolation protocol by omitting centrifugation of the lysate. This deletion of centrifugation results in only a minor contamination of the isolated DNA with
- RNA Analysis ofthe genomic DNA isolated as described above was performed by electrophoreses thereof in 1% agarose gel and staining with ethidium bromide. Lanes 1 and 2 of Fig. 3 are genomic DNA (3 ⁇ g/lane), and lanes 3 and 4 are genomic DNA digested for 2 hours with EcoRI. As is apparent in Figure 3, only a residual amount of RNA was detected in the low molecular weight region of the agarose gel by the ethidium bromide staining. Apparently, spooling DNA onto a pipette tip removes mainly DNA, while most of the partially hydrolyzed RNA (as indicated by its low molecular weight) remains in the lysate.
- the presence of a reducing agent is not necessary for the isolation of DNA and the lysing solution can have pH within the range 6 - 12.
- the alkaline pH can be adjusted with NaOH, KOH or other organic or inorganic alkaline reagents. The best results are believed to be obtained when the lysate has a pH between 8 - 9.
- the unexpected and rapid hydrolysis of RNA occurring at pH 8 - pH 9 can be attributed to the presence of the chaotropic agent. This new finding allows for isolation of good quality DNA in a simple, one-step method.
- the protocol for DNA isolation without centrifugation can be completed in less than 10 minutes. This is believed to be the fastest and simplest method of genomic DNA isolation. Importantly, the only equipment required for this method are tubes and pipettes. This allows for performing the DNA isolation on a field trip or elsewhere with a limited access to laboratory equipment.
- Rat spleen (127 mg) was homogenized in a hand held glass- Teflon homogenizer with 5 ml of the lysing solution described in Example 5. The homogenate was centrifuged at 10,000 g for 5 minutes. The supernatant was transferred to a new tobe and DNA was precipitated and washed as in Example 5. The isolated DNA exhibited a 260/280 ratio 1.76, and the yield was
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96925355A EP0843724B2 (en) | 1995-07-31 | 1996-07-18 | Solution containing chaotropic agent and process using it for isolation of dna, rna and proteins |
DE69632466T DE69632466T3 (en) | 1995-07-31 | 1996-07-18 | SOLUTION THAT CONTAINS CHAOTROPIC AGENTS AND USE OF THIS SOLUTION IN PROCESSES FOR ISOLATING DNA, RNA AND PROTEINS |
AU65480/96A AU6548096A (en) | 1995-07-31 | 1996-07-18 | Solution containing chaotropic agent and process using it for isolation of dna, rna and proteins |
AT96925355T ATE266723T1 (en) | 1995-07-31 | 1996-07-18 | SOLUTION CONTAINING CHAOTROPIC AGENTS AND USE OF THIS SOLUTION IN PROCEDURES FOR ISOLATION OF DNA, RNA AND PROTEINS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/509,164 | 1995-07-31 | ||
US08/509,164 US5945515A (en) | 1995-07-31 | 1995-07-31 | Product and process for isolating DNA, RNA and proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997005248A2 true WO1997005248A2 (en) | 1997-02-13 |
WO1997005248A3 WO1997005248A3 (en) | 1997-03-06 |
Family
ID=24025561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/011875 WO1997005248A2 (en) | 1995-07-31 | 1996-07-18 | Solution containing chaotropic agent and process using it for isolation of dna, rna and proteins |
Country Status (6)
Country | Link |
---|---|
US (1) | US5945515A (en) |
EP (1) | EP0843724B2 (en) |
AT (1) | ATE266723T1 (en) |
AU (1) | AU6548096A (en) |
DE (1) | DE69632466T3 (en) |
WO (1) | WO1997005248A2 (en) |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029840A1 (en) * | 1997-12-09 | 1999-06-17 | The Perkin-Elmer Corporation | Methods of nucleic acid isolation |
DE19836559A1 (en) * | 1998-08-12 | 2000-03-23 | Antigen Gmbh | Blood collection vessel |
US6043354A (en) * | 1996-01-31 | 2000-03-28 | Invitek Gmbh | Method for the simultaneous isolation of genomic DNA and high-purity RNA |
US6248535B1 (en) | 1999-12-20 | 2001-06-19 | University Of Southern California | Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens |
DE10006662A1 (en) * | 2000-02-15 | 2001-08-23 | Antigen Produktions Gmbh | Sample vessel for stabilizing and isolating nucleic acid, contains a lytic solution that stabilizes nucleic acid and a solid phase that binds it, especially for sampling whole blood |
US6326147B1 (en) | 1999-05-13 | 2001-12-04 | The Perkin-Elmer Corporation | Methods, apparatus, articles of manufacture, and user interfaces for performing automated biological assay preparation and macromolecule purification |
KR20020029476A (en) * | 2000-10-13 | 2002-04-19 | 박제철 | Lysis buffer reagent for gene extraction by one step |
KR20020029477A (en) * | 2000-10-13 | 2002-04-19 | 박제철 | Method for gene extraction by one step |
WO2003019131A2 (en) * | 2001-08-29 | 2003-03-06 | Hexal Pharma Gmbh | Method and device for preparing a sample of biological origin in order to determine at least one constituent contained therein |
WO2003046146A2 (en) | 2001-11-28 | 2003-06-05 | Applera Corporation | Compositions and methods of selective nucleic acid isolation |
WO2003104251A3 (en) * | 2002-06-07 | 2004-07-15 | Dna Genotek Inc | Composition and methods for obtaining nucleic acids from sputum |
KR100454869B1 (en) * | 2001-07-13 | 2004-11-03 | 주식회사 인트론바이오테크놀로지 | Cell lysis buffer for extracting DNA and extraction method by using thereof |
WO2004108925A1 (en) * | 2003-06-04 | 2004-12-16 | Qiagen As | Method for sequentially isolating dna and rna from the same nucleic acid-containing sample |
US6905821B2 (en) | 2001-03-02 | 2005-06-14 | Response Genetics, Inc. | Method of determining Dihydropyrimidine dehydrogenase gene expression |
WO2005075642A1 (en) * | 2004-02-04 | 2005-08-18 | Universitá Degli Studi Di Padova | Method for simultaneous extraction of nucleic acids from a biological sample |
US7005278B2 (en) | 2001-03-02 | 2006-02-28 | Danenberg Kathleen D | Method of determining dihydropyrimidine dehydrogenase gene expression |
EP1631685A2 (en) * | 2003-05-19 | 2006-03-08 | Brandeis University | Nucleic acid processing methods, kits and devices |
US7049059B2 (en) | 2000-12-01 | 2006-05-23 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression |
US7132238B2 (en) | 2000-12-01 | 2006-11-07 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
US7138507B2 (en) | 2001-06-14 | 2006-11-21 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on glutathione-s transferase pi expression |
EP1932913A1 (en) | 2006-12-11 | 2008-06-18 | Roche Diagnostics GmbH | Nucleic acid isolation using polidocanol and derivatives |
WO2009085355A3 (en) * | 2007-10-01 | 2009-10-15 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
US8026062B2 (en) | 2000-12-01 | 2011-09-27 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US8097717B2 (en) | 2006-12-11 | 2012-01-17 | Roche Molecular Systems, Inc. | Compositions comprising polidocanol and derivatives |
US8158357B2 (en) | 2005-03-16 | 2012-04-17 | Dna Genotek Inc. | Compositions and method for storage of nucleic acid from bodily fluids |
US8221381B2 (en) | 2005-12-09 | 2012-07-17 | Dna Genotek Inc. | Container system for releasably storing a substance |
AU2011291680B2 (en) * | 2010-08-18 | 2014-01-09 | Toray Industries, Inc. | Solution for extraction of RNA |
AU2012211365B2 (en) * | 2007-10-01 | 2014-01-09 | Longhorn Vaccines & Diagnostics, Llc | Biological specimen collection and transport system and methods of use |
CN104471074A (en) * | 2012-03-28 | 2015-03-25 | 长角牛疫苗和诊断有限责任公司 | Compositions and methods for the collection and isolation of nucleic acids from biological specimens |
EP2784509A3 (en) * | 2013-03-28 | 2015-08-12 | FUJIFILM Corporation | Chromatography method, and chromatography kit |
GB2538955A (en) * | 2015-05-29 | 2016-12-07 | Ge Healthcare Uk Ltd | Improvements in and relating to extracting biological analytes |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
US9777045B2 (en) | 2007-08-27 | 2017-10-03 | Longhorn Vaccines And Diagnostics, Llc | Immunogenic compositions and methods |
US9845489B2 (en) | 2010-07-26 | 2017-12-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
US9976136B2 (en) | 2015-05-14 | 2018-05-22 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
US9999217B2 (en) | 2010-07-26 | 2018-06-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA, and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US10064404B2 (en) | 2014-06-10 | 2018-09-04 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
US10568317B2 (en) | 2015-12-08 | 2020-02-25 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
US11002646B2 (en) | 2011-06-19 | 2021-05-11 | DNA Genotek, Inc. | Devices, solutions and methods for sample collection |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US11284867B2 (en) | 2019-06-20 | 2022-03-29 | Spectrum Solutions L.L.C. | Sample collection system including a sample collection vessel, sealing cap, and reagent chamber and valve assembly in the sealing cap |
US11655495B2 (en) | 2017-01-16 | 2023-05-23 | Spectrum Solutions L.L.C. | Nucleic acid preservation solution and methods of manufacture and use |
US11712692B2 (en) | 2018-11-20 | 2023-08-01 | Spectrum Solutions L.L.C. | Sample collection system including sealing cap and valve |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6475388B1 (en) | 1996-11-13 | 2002-11-05 | Transgenomic, Inc. | Method and system for RNA analysis by matched ion polynucleotide chromatography |
US6576133B2 (en) | 1996-11-13 | 2003-06-10 | Transgenomic, Inc | Method and system for RNA analysis by matched ion polynucleotide chromatography |
US6258264B1 (en) | 1998-04-10 | 2001-07-10 | Transgenomic, Inc. | Non-polar media for polynucleotide separations |
US7569342B2 (en) | 1997-12-10 | 2009-08-04 | Sierra Molecular Corp. | Removal of molecular assay interferences |
US6777210B1 (en) * | 1998-09-24 | 2004-08-17 | Ambion, Inc. | Method and reagents for inactivating ribonucleases RNase A, RNase I and RNase T1 |
US6936414B2 (en) * | 1999-12-22 | 2005-08-30 | Abbott Laboratories | Nucleic acid isolation method and kit |
US6548256B2 (en) | 2000-07-14 | 2003-04-15 | Eppendorf 5 Prime, Inc. | DNA isolation method and kit |
US20030228600A1 (en) * | 2000-07-14 | 2003-12-11 | Eppendorf 5 Prime, Inc. | DNA isolation method and kit |
US6521411B2 (en) | 2000-09-28 | 2003-02-18 | Transgenomic, Inc. | Method and system for the preparation of cDNA |
WO2002044413A2 (en) * | 2000-12-01 | 2002-06-06 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and her2-neu gene expression and correlation of levels thereof with survival rates |
KR100426544B1 (en) * | 2000-12-08 | 2004-04-13 | 바이오코아 주식회사 | Method for extracting viral nucleic acids from serum or plasma and compositions therefor |
US7148343B2 (en) * | 2001-10-12 | 2006-12-12 | Gentra Systems, Inc. | Compositions and methods for using a solid support to purify RNA |
US7893228B2 (en) * | 2001-10-12 | 2011-02-22 | Qiagen North American Holdings, Inc. | Compositions and methods for using a solid support to purify RNA |
US20050032105A1 (en) * | 2001-10-12 | 2005-02-10 | Bair Robert Jackson | Compositions and methods for using a solid support to purify DNA |
US6667165B2 (en) | 2001-11-13 | 2003-12-23 | Eppendorf Ag | Method and compositions for reversible inhibition of thermostable polymerases |
JP2006520199A (en) | 2003-03-19 | 2006-09-07 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | Plasminogen activator inhibitor-1 (PAI-1) haplotype useful as an indicator of patient outcome |
CN100352032C (en) * | 2003-03-26 | 2007-11-28 | 信越半导体株式会社 | Heat treatment-purpose wafer support tool, and heat treatment device |
US7267950B2 (en) * | 2003-05-01 | 2007-09-11 | Veridex, Lcc | Rapid extraction of RNA from cells and tissues |
US7488579B2 (en) * | 2003-05-06 | 2009-02-10 | Biochain Institute, Inc. | Methods and compositions to extract DNA, RNA and protein simultaneously from biological samples |
US20050042660A1 (en) * | 2003-07-31 | 2005-02-24 | Hall Gerald Edward | Devices and methods for isolating RNA |
US20050026153A1 (en) * | 2003-07-31 | 2005-02-03 | Iannotti Claudia A. | Devices and methods for isolating RNA |
CA2549985C (en) * | 2003-12-16 | 2011-05-24 | Gentra Systems, Inc. | Formulations and methods for denaturing proteins |
US20050227225A1 (en) * | 2004-04-07 | 2005-10-13 | Roche Molecular Systems, Inc. | Stabilization of biomolecules in samples |
US20060099567A1 (en) * | 2004-04-08 | 2006-05-11 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
SG151298A1 (en) * | 2004-04-08 | 2009-04-30 | Biomatrica Inc | Integration of sample storage and sample management for life science |
US20080176209A1 (en) * | 2004-04-08 | 2008-07-24 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
US7794932B2 (en) * | 2004-04-16 | 2010-09-14 | Piotr Chomczynski | Reagents and methods for isolation of purified RNA |
AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
US8420603B2 (en) * | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
US20060099605A1 (en) * | 2004-11-11 | 2006-05-11 | Hall Gerald E Jr | Devices and methods for isolating RNA |
US20060272078A1 (en) * | 2004-10-29 | 2006-12-07 | Riccardo Polinelli | Apparatus and methodology to mitigate fogging on dual lens sports goggle |
AU2005305012C1 (en) | 2004-11-05 | 2012-07-19 | Qiagen North American Holdings, Inc. | Compositions and methods for purifying nucleic acids from stabilization reagents |
BRPI0518662B1 (en) | 2004-11-30 | 2020-12-22 | Merial, Inc. | process and apparatus for lysis of biological compounds |
US7727718B2 (en) * | 2005-01-04 | 2010-06-01 | Molecular Research Center, Inc. | Reagents for storage and preparation of samples for DNA analysis |
JP2008535475A (en) * | 2005-02-18 | 2008-09-04 | アブラクシス バイオサイエンス、インコーポレイテッド | Q3SPARC deletion mutant and use thereof |
US20060223073A1 (en) * | 2005-03-31 | 2006-10-05 | Boyes Barry E | Methods of using a DNase I-like enzyme |
US20060223072A1 (en) * | 2005-03-31 | 2006-10-05 | Boyes Barry E | Methods of using a DNase I-like enzyme |
US8632970B2 (en) | 2005-05-09 | 2014-01-21 | Affymetrix, Inc. | Multiplex capture of nucleic acids |
US8628918B2 (en) * | 2005-05-09 | 2014-01-14 | Affymetrix, Inc. | Multiplex capture of nucleic acids |
US7803541B2 (en) | 2005-05-12 | 2010-09-28 | Panomics, Inc. | Multiplex branched-chain DNA assays |
US20060270843A1 (en) * | 2005-05-26 | 2006-11-30 | Hall Gerald E Jr | Methods for isolation of nucleic acids |
KR100622606B1 (en) | 2005-06-16 | 2006-09-11 | (주)엘피스바이오텍 | Composition for the purification of plasmid dna by one step and rapid purification method thereof |
CN104673903B (en) * | 2005-06-20 | 2018-11-13 | 领先细胞医疗诊断有限公司 | The method for detecting the nucleic acid in individual cells and identifying rare cells in heterogeneous maxicell group |
US20090148458A1 (en) * | 2005-06-23 | 2009-06-11 | The University Of British Columbia | Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy |
US20070054168A1 (en) * | 2005-09-06 | 2007-03-08 | Hao Chang | Zinc/air cell |
WO2007044427A2 (en) * | 2005-10-05 | 2007-04-19 | Panomics, Inc. | Detection of nucleic acids from whole blood |
RU2394915C2 (en) * | 2006-03-24 | 2010-07-20 | Александр Борисович Четверин | Non-contact methods of detecting molecular colonies, sets of reagents and device for realising said methods |
US7687254B2 (en) * | 2006-07-11 | 2010-03-30 | Case Western Reserve University | Phenol-free method of isolating DNA |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
AU2008240117B2 (en) * | 2007-04-13 | 2013-12-05 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
EP2191012A1 (en) * | 2007-09-21 | 2010-06-02 | Streck, Inc. | Nucleic acid isolation in preserved whole blood |
WO2009059430A1 (en) * | 2007-11-07 | 2009-05-14 | The University Of British Columbia | Microfluidic device and method of using same |
US20090143570A1 (en) * | 2007-11-30 | 2009-06-04 | Ge Healthcare Bio-Sciences Corp. | Method for isolation of genomic dna, rna and proteins from a single sample |
WO2010033652A1 (en) * | 2008-09-17 | 2010-03-25 | Ge Healthcare Bio-Sciences Corp. | Method for small rna isolation |
US8846878B1 (en) | 2009-01-23 | 2014-09-30 | Cubrc Corporation | Method and device for isolating a protein sample |
US9024008B2 (en) | 2010-07-07 | 2015-05-05 | Diagon Ltd. | Procedure for the specific isolation of total DNA content of bacterial germs and a kit for this purpose |
US9046507B2 (en) | 2010-07-29 | 2015-06-02 | Gen-Probe Incorporated | Method, system and apparatus for incorporating capacitive proximity sensing in an automated fluid transfer procedure |
ES2648564T3 (en) | 2010-10-21 | 2018-01-04 | Advanced Cell Diagnostics, Inc. | Ultrasensitive method for in situ detection of nucleic acids |
WO2012068519A2 (en) | 2010-11-19 | 2012-05-24 | Sirius Genomics Inc. | Markers associated with response to activated protein c administration, and uses thereof |
US8530228B2 (en) * | 2010-12-28 | 2013-09-10 | Bexmart | Integrated versatile and systems preparation of specimens |
CN102250876B (en) | 2011-05-18 | 2014-08-13 | 李学敬 | Method for separating and purifying RNA in biological material |
WO2013067268A1 (en) | 2011-11-03 | 2013-05-10 | Tripath Imaging, Inc. | Methods and compositions for preparing samples for immunostaining |
EP3494989A1 (en) | 2012-01-26 | 2019-06-12 | Longhorn Vaccines and Diagnostics, LLC | Composite antigenic sequences and vaccines |
EP2847330B1 (en) | 2012-05-09 | 2018-04-18 | Bio-Rad Laboratories, Inc. | Buffer for one-step dna extraction |
CN102876663B (en) * | 2012-10-10 | 2014-07-30 | 北京百泰克生物技术有限公司 | Reagent and method for rapidly extracting main RNA (ribonucleic acid) from liquid sample |
JP6767374B2 (en) | 2014-10-20 | 2020-10-14 | ジェン−プローブ・インコーポレーテッド | Red blood cell lysing solution |
GB2531741A (en) * | 2014-10-28 | 2016-05-04 | Bisn Laboratory Services Ltd | Molecular and bioinformatics methods for direct sequencing |
ES2893100T3 (en) | 2015-10-12 | 2022-02-08 | Advanced Cell Diagnostics Inc | In situ detection of nucleotide variants in samples with a high level of noise, and related compositions and methods |
WO2017114844A1 (en) * | 2015-12-28 | 2017-07-06 | Koninklijke Philips N.V. | Nucleic acid purification system using a single wash and elution buffer solution |
DE202017007130U1 (en) | 2016-04-27 | 2019-08-29 | Gen-Probe Inc. | Lysis reagent for blood cells |
CN110225980B (en) | 2016-11-21 | 2023-01-06 | 纳米线科技公司 | Chemical compositions and methods of use thereof |
CN110430756B (en) | 2017-03-17 | 2022-06-03 | 先正达参股股份有限公司 | Methods and compositions for preserving tissue and nucleic acids |
SG11202011274YA (en) | 2018-05-14 | 2020-12-30 | Nanostring Technologies Inc | Chemical compositions and methods of using same |
CN111269284B (en) * | 2018-12-04 | 2023-07-25 | 中国科学院大连化学物理研究所 | Reagents and methods for simultaneous separation of proteins and RNAs in cytoplasm and nucleus |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992000983A1 (en) * | 1990-07-13 | 1992-01-23 | Microprobe Corporation | Non-corrosive composition and methods useful for the extraction of nucleic acids |
US5128247A (en) * | 1989-08-14 | 1992-07-07 | Board Of Regents, The University Of Texas System | Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources |
US5162507A (en) * | 1987-05-11 | 1992-11-10 | Cetus Corporation | Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms |
EP0544034A1 (en) * | 1991-11-28 | 1993-06-02 | Siemens Aktiengesellschaft | Method for reconstructing the correct sequence of communication cells |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3147185A (en) * | 1959-09-10 | 1964-09-01 | Merck & Co Inc | Process for purifying viral substances and composition |
US3389133A (en) * | 1966-08-10 | 1968-06-18 | Schwarz Biores Inc | Process for isolating and purifying soluble ribonucleic acid |
US4843155A (en) * | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
US5234809A (en) * | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
US5010183A (en) * | 1989-07-07 | 1991-04-23 | Macfarlane Donald E | Process for purifying DNA and RNA using cationic detergents |
US5130423A (en) * | 1990-07-13 | 1992-07-14 | Microprobe Corporation | Non-corrosive compositions and methods useful for the extraction of nucleic acids |
US5346994A (en) * | 1992-01-28 | 1994-09-13 | Piotr Chomczynski | Shelf-stable product and process for isolating RNA, DNA and proteins |
US5407810A (en) * | 1993-08-20 | 1995-04-18 | Genentech, Inc. | Aqueous multiple-phase isolation of polypeptide |
-
1995
- 1995-07-31 US US08/509,164 patent/US5945515A/en not_active Expired - Lifetime
-
1996
- 1996-07-18 EP EP96925355A patent/EP0843724B2/en not_active Expired - Lifetime
- 1996-07-18 AU AU65480/96A patent/AU6548096A/en not_active Abandoned
- 1996-07-18 WO PCT/US1996/011875 patent/WO1997005248A2/en active IP Right Grant
- 1996-07-18 AT AT96925355T patent/ATE266723T1/en not_active IP Right Cessation
- 1996-07-18 DE DE69632466T patent/DE69632466T3/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5162507A (en) * | 1987-05-11 | 1992-11-10 | Cetus Corporation | Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms |
US5128247A (en) * | 1989-08-14 | 1992-07-07 | Board Of Regents, The University Of Texas System | Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources |
WO1992000983A1 (en) * | 1990-07-13 | 1992-01-23 | Microprobe Corporation | Non-corrosive composition and methods useful for the extraction of nucleic acids |
EP0544034A1 (en) * | 1991-11-28 | 1993-06-02 | Siemens Aktiengesellschaft | Method for reconstructing the correct sequence of communication cells |
Non-Patent Citations (2)
Title |
---|
ANALYTICAL BIOCHEMISTRY, vol. 207, no. 1, 15 November 1992, US, pages 197-201, XP000611804 NELSON J.E. AND KRAWETZ S.A.: "Purification of cloned and genomic DNA by guanidine thiocyanate/isobutyl alcohol fractionation" * |
J. MICROBIOL. METHODS, vol. 19, no. 3, 1994, pages 167-172, XP000610898 LEMA M.W ET AL.: "A general method for the extraction of DNA from bacteria" * |
Cited By (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6043354A (en) * | 1996-01-31 | 2000-03-28 | Invitek Gmbh | Method for the simultaneous isolation of genomic DNA and high-purity RNA |
US5972613A (en) * | 1997-12-09 | 1999-10-26 | The Perkin-Elmer Corporation | Methods of nucleic acid isolation |
WO1999029840A1 (en) * | 1997-12-09 | 1999-06-17 | The Perkin-Elmer Corporation | Methods of nucleic acid isolation |
EP2206792A1 (en) * | 1998-08-12 | 2010-07-14 | PreAnalytiX GmbH | Vessel for blood sampling |
USRE43389E1 (en) | 1998-08-12 | 2012-05-15 | Preanalytix Gmbh | Vessel for blood sampling |
DE19836559A1 (en) * | 1998-08-12 | 2000-03-23 | Antigen Gmbh | Blood collection vessel |
EP2071037A1 (en) * | 1998-08-12 | 2009-06-17 | PreAnalytiX GmbH | Vessel for blood sampling |
US6326147B1 (en) | 1999-05-13 | 2001-12-04 | The Perkin-Elmer Corporation | Methods, apparatus, articles of manufacture, and user interfaces for performing automated biological assay preparation and macromolecule purification |
US6610488B2 (en) | 1999-12-20 | 2003-08-26 | University Of Southern California | Isolation of RNA, DNA and proteins from formalin-fixed paraffin-embedded tissue specimens |
US7919280B2 (en) | 1999-12-20 | 2011-04-05 | University Of Southern California | Method for isolation of DNA, RNA and proteins from formalin-fixed paraffin-embedded tissue specimens |
US6613518B2 (en) | 1999-12-20 | 2003-09-02 | University Of Sourthern California | Quantitative measurement of gene expression based on isolation of RNA from formalin-fixed paraffin-embedded tissue specimens |
US6248535B1 (en) | 1999-12-20 | 2001-06-19 | University Of Southern California | Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens |
WO2001060517A3 (en) * | 2000-02-15 | 2002-08-22 | Antigen Produktions Gmbh | Container for nucleic acid analysis |
US7282371B2 (en) | 2000-02-15 | 2007-10-16 | Preanalytix Gmbh | Container for nucleic acid analysis |
EP2189220A1 (en) * | 2000-02-15 | 2010-05-26 | PreAnalytiX GmbH | Vessel for nucleic acid analysis |
WO2001060517A2 (en) | 2000-02-15 | 2001-08-23 | Antigene Biotech Gmbh | Container for nucleic acid analysis |
DE10006662A1 (en) * | 2000-02-15 | 2001-08-23 | Antigen Produktions Gmbh | Sample vessel for stabilizing and isolating nucleic acid, contains a lytic solution that stabilizes nucleic acid and a solid phase that binds it, especially for sampling whole blood |
KR20020029477A (en) * | 2000-10-13 | 2002-04-19 | 박제철 | Method for gene extraction by one step |
KR20020029476A (en) * | 2000-10-13 | 2002-04-19 | 박제철 | Lysis buffer reagent for gene extraction by one step |
US7049059B2 (en) | 2000-12-01 | 2006-05-23 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression |
US8586311B2 (en) | 2000-12-01 | 2013-11-19 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression |
US8026062B2 (en) | 2000-12-01 | 2011-09-27 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors |
US7560543B2 (en) | 2000-12-01 | 2009-07-14 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression |
US7732144B2 (en) | 2000-12-01 | 2010-06-08 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression |
US7132238B2 (en) | 2000-12-01 | 2006-11-07 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
US7005278B2 (en) | 2001-03-02 | 2006-02-28 | Danenberg Kathleen D | Method of determining dihydropyrimidine dehydrogenase gene expression |
US6905821B2 (en) | 2001-03-02 | 2005-06-14 | Response Genetics, Inc. | Method of determining Dihydropyrimidine dehydrogenase gene expression |
US6956111B2 (en) | 2001-03-02 | 2005-10-18 | Response Genetics, Inc. | Method of determining dihydropyrimidine dehydrogenase gene expression |
US7138507B2 (en) | 2001-06-14 | 2006-11-21 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on glutathione-s transferase pi expression |
KR100454869B1 (en) * | 2001-07-13 | 2004-11-03 | 주식회사 인트론바이오테크놀로지 | Cell lysis buffer for extracting DNA and extraction method by using thereof |
WO2003019131A3 (en) * | 2001-08-29 | 2003-11-27 | Hexal Pharma Gmbh | Method and device for preparing a sample of biological origin in order to determine at least one constituent contained therein |
US7456024B2 (en) | 2001-08-29 | 2008-11-25 | Hexal Pharma Gmbh | Method and device for preparing a sample of biological origin in order to determine at least one constituent contained therein |
WO2003019131A2 (en) * | 2001-08-29 | 2003-03-06 | Hexal Pharma Gmbh | Method and device for preparing a sample of biological origin in order to determine at least one constituent contained therein |
EP1448799A2 (en) * | 2001-11-28 | 2004-08-25 | Applera Corporation | Compositions and methods of selective nucleic acid isolation |
EP1448799B1 (en) * | 2001-11-28 | 2009-11-18 | Applied Biosystems, LLC | Kits and methods of selective nucleic acid isolation |
US8865405B2 (en) | 2001-11-28 | 2014-10-21 | Applied Biosystems Llc | Compositions and methods of selective nucleic acid isolation |
US7537898B2 (en) | 2001-11-28 | 2009-05-26 | Applied Biosystems, Llc | Compositions and methods of selective nucleic acid isolation |
WO2003046146A2 (en) | 2001-11-28 | 2003-06-05 | Applera Corporation | Compositions and methods of selective nucleic acid isolation |
US8507198B2 (en) | 2001-11-28 | 2013-08-13 | Applied Biosystems, Llc | Compositions and methods of selective nucleic acid isolation |
US7208271B2 (en) | 2001-11-28 | 2007-04-24 | Applera Corporation | Compositions and methods of selective nucleic acid isolation |
US10619187B2 (en) | 2002-06-07 | 2020-04-14 | Dna Genotek Inc. | Compositions and methods for obtaining nucleic acids from sputum |
US9523115B2 (en) | 2002-06-07 | 2016-12-20 | Dna Genotek Inc. | Compositions and methods for obtaining nucleic acids from sputum |
WO2003104251A3 (en) * | 2002-06-07 | 2004-07-15 | Dna Genotek Inc | Composition and methods for obtaining nucleic acids from sputum |
US7482116B2 (en) | 2002-06-07 | 2009-01-27 | Dna Genotek Inc. | Compositions and methods for obtaining nucleic acids from sputum |
US11572581B2 (en) | 2002-06-07 | 2023-02-07 | DNA Genotek, Inc. | Compositions and methods for obtaining nucleic acids from sputum |
JP4836795B2 (en) * | 2003-05-19 | 2011-12-14 | ブランデイズ ユニバーシティー | Nucleic acid processing method, kit, and apparatus |
US9279121B2 (en) | 2003-05-19 | 2016-03-08 | Lawrence J Wangh | Nucleic acid processing kits and devices |
EP1631685A2 (en) * | 2003-05-19 | 2006-03-08 | Brandeis University | Nucleic acid processing methods, kits and devices |
JP2006528002A (en) * | 2003-05-19 | 2006-12-14 | ブランデイズ ユニバーシティー | Nucleic acid processing method, kit, and apparatus |
EP1631685A4 (en) * | 2003-05-19 | 2007-08-29 | Univ Brandeis | Nucleic acid processing methods, kits and devices |
US7465562B2 (en) | 2003-05-19 | 2008-12-16 | Brandeis University | Nucleic acid processing methods, kits and devices |
WO2004108925A1 (en) * | 2003-06-04 | 2004-12-16 | Qiagen As | Method for sequentially isolating dna and rna from the same nucleic acid-containing sample |
WO2005075642A1 (en) * | 2004-02-04 | 2005-08-18 | Universitá Degli Studi Di Padova | Method for simultaneous extraction of nucleic acids from a biological sample |
US8470536B2 (en) | 2005-03-16 | 2013-06-25 | Dna Genotek Inc. | Compositions and method for storage of nucleic acid from bodily fluids |
US8158357B2 (en) | 2005-03-16 | 2012-04-17 | Dna Genotek Inc. | Compositions and method for storage of nucleic acid from bodily fluids |
US8221381B2 (en) | 2005-12-09 | 2012-07-17 | Dna Genotek Inc. | Container system for releasably storing a substance |
US9080204B2 (en) | 2006-09-12 | 2015-07-14 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for rapid, real-time detection of influenza a virus (H1N1) Swine 2009 |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US8192958B2 (en) | 2006-12-11 | 2012-06-05 | Roche Molecular Systems, Inc. | Nucleic acid isolation using polidocanol and derivatives |
EP1932913A1 (en) | 2006-12-11 | 2008-06-18 | Roche Diagnostics GmbH | Nucleic acid isolation using polidocanol and derivatives |
US8097717B2 (en) | 2006-12-11 | 2012-01-17 | Roche Molecular Systems, Inc. | Compositions comprising polidocanol and derivatives |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US10596250B2 (en) | 2007-08-27 | 2020-03-24 | Longhorn Vaccines And Diagnostics, Llc | Methods of treating and preventing influenza infections |
US9777045B2 (en) | 2007-08-27 | 2017-10-03 | Longhorn Vaccines And Diagnostics, Llc | Immunogenic compositions and methods |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8415330B2 (en) | 2007-10-01 | 2013-04-09 | Longhorn Vaccines & Diagnostics, Llc | Biological specimen collection and transport system and method of use |
WO2009085355A3 (en) * | 2007-10-01 | 2009-10-15 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
EP3020832A1 (en) * | 2007-10-01 | 2016-05-18 | Longhorn Vaccines and Diagnostics, LLC | Biological specimen collection and transport system and methods of use |
US9416416B2 (en) | 2007-10-01 | 2016-08-16 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection/transport compositions and methods |
US8084443B2 (en) | 2007-10-01 | 2011-12-27 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
AU2012211365B2 (en) * | 2007-10-01 | 2014-01-09 | Longhorn Vaccines & Diagnostics, Llc | Biological specimen collection and transport system and methods of use |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
US8293467B2 (en) | 2007-10-01 | 2012-10-23 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
EP2535428A3 (en) * | 2007-10-01 | 2013-03-27 | Longhorn Vaccines & Diagnostics, LLC | Biological specimen collection and transport system and methods of use |
US9845489B2 (en) | 2010-07-26 | 2017-12-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
US9999217B2 (en) | 2010-07-26 | 2018-06-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA, and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
AU2011291680B2 (en) * | 2010-08-18 | 2014-01-09 | Toray Industries, Inc. | Solution for extraction of RNA |
US11592368B2 (en) | 2011-06-19 | 2023-02-28 | DNA Genotek, Inc. | Method for collecting and preserving a biological sample |
US11549870B2 (en) | 2011-06-19 | 2023-01-10 | DNA Genotek, Inc. | Cell preserving solution |
US11536632B2 (en) | 2011-06-19 | 2022-12-27 | DNA Genotek, Inc. | Biological collection system |
US11002646B2 (en) | 2011-06-19 | 2021-05-11 | DNA Genotek, Inc. | Devices, solutions and methods for sample collection |
CN104471074A (en) * | 2012-03-28 | 2015-03-25 | 长角牛疫苗和诊断有限责任公司 | Compositions and methods for the collection and isolation of nucleic acids from biological specimens |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
EP2784509A3 (en) * | 2013-03-28 | 2015-08-12 | FUJIFILM Corporation | Chromatography method, and chromatography kit |
US10772319B2 (en) | 2014-06-10 | 2020-09-15 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
US10064404B2 (en) | 2014-06-10 | 2018-09-04 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
US11672247B2 (en) | 2014-06-10 | 2023-06-13 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
US9976136B2 (en) | 2015-05-14 | 2018-05-22 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
US10087439B1 (en) | 2015-05-14 | 2018-10-02 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
GB2538955A (en) * | 2015-05-29 | 2016-12-07 | Ge Healthcare Uk Ltd | Improvements in and relating to extracting biological analytes |
US11116205B2 (en) | 2015-12-08 | 2021-09-14 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
US10568317B2 (en) | 2015-12-08 | 2020-02-25 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
US11655495B2 (en) | 2017-01-16 | 2023-05-23 | Spectrum Solutions L.L.C. | Nucleic acid preservation solution and methods of manufacture and use |
US11712692B2 (en) | 2018-11-20 | 2023-08-01 | Spectrum Solutions L.L.C. | Sample collection system including sealing cap and valve |
US11284867B2 (en) | 2019-06-20 | 2022-03-29 | Spectrum Solutions L.L.C. | Sample collection system including a sample collection vessel, sealing cap, and reagent chamber and valve assembly in the sealing cap |
US11547392B2 (en) | 2019-06-20 | 2023-01-10 | Spectrum Solutions L.L.C. | Method of collecting and preserving a biological sample |
US11701094B2 (en) | 2019-06-20 | 2023-07-18 | Spectrum Solutions L.L.C. | Sample collection system including valve and plug assemblies |
Also Published As
Publication number | Publication date |
---|---|
ATE266723T1 (en) | 2004-05-15 |
DE69632466D1 (en) | 2004-06-17 |
EP0843724B2 (en) | 2011-07-20 |
DE69632466T3 (en) | 2012-05-24 |
EP0843724B1 (en) | 2004-05-12 |
WO1997005248A3 (en) | 1997-03-06 |
AU6548096A (en) | 1997-02-26 |
EP0843724A2 (en) | 1998-05-27 |
US5945515A (en) | 1999-08-31 |
DE69632466T2 (en) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5945515A (en) | Product and process for isolating DNA, RNA and proteins | |
US10947527B2 (en) | Compositions and methods for purifying nucleic acids from stabilization reagents | |
US5346994A (en) | Shelf-stable product and process for isolating RNA, DNA and proteins | |
US10738069B2 (en) | Method for isolating nucleic acids | |
EP1618194B1 (en) | Compositions and methods for using a solid support to purify rna | |
US5972613A (en) | Methods of nucleic acid isolation | |
EP2066792B1 (en) | Nucleic acid purification method using anion exchange | |
JP2002531126A (en) | Formulations and methods for isolation of nucleic acids from any complex starting material and subsequent complex gene analysis | |
WO2007113614A1 (en) | A method for rapid isolation of rna and a kit thereof | |
JP2002501759A (en) | Improved method for isolating nucleic acids | |
CA2694411A1 (en) | An improved nucleic acid purification method | |
US20040126796A1 (en) | Extraction of DNA from biological samples | |
US20090130687A1 (en) | Formulations and method isolating nucleic acids from arbitrary complex starting materials and subsequent complex genetic materials | |
WO2002055737A1 (en) | Compositions and methods for dna purification from whole blood | |
Murphy et al. | Improved nucleic acid organic extraction through use of a unique gel barrier material | |
JP2004329176A (en) | Method for isolating rna | |
DE4422044A1 (en) | Simple isolation and purificn. of nucleic acid from various samples | |
AU2002255555B2 (en) | Method to isolate DNA | |
JPH11196869A (en) | Isolation of liponucleic acid | |
JP2001299341A (en) | Improved method of isolating ribonucleic acid | |
GB2419594A (en) | Surfactant primary, secondary and tertiary amines, and amine oxides, and their use in stabilizing or isolating nucleic acids | |
Parimoo et al. | Sample Preparation in RNA Analysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996925355 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996925355 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996925355 Country of ref document: EP |